Ligand Pharmaceuticals Incorporated has entered into a worldwide license agreement with ABBA Therapeutics AG, a Swiss biotechnology company developing innovative immuno-oncology therapies. Under the license, ABBA will be able to use the OmniRat®, OmniMouse® and OmniFlic® platforms to generate fully human mono- and bispecific antibodies. Ligand is to receive an initial access payment, and will be eligible to receive clinical milestone payments and royalties for each successful OmniAb antibody. ABBA will be responsible for all costs related to the program.
OmniAb® will provide ABBA with industry-leading technology for generation of novel antibody therapeutics to further their therapeutic strategy,” said John Higgins, Chief Executive Officer of Ligand. “This is the third OmniAb license deal since the close of the OMT acquisition and the 19th overall OmniAb Ligand partner, and continues to show the licensing power that the OmniAb franchise brings to Ligand.”